| Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases S Frentzas, E Simoneau, VL Bridgeman, PB Vermeulen, S Foo, ... Nature medicine 22 (11), 1294-1302, 2016 | 431 | 2016 |
| International consensus guidelines for scoring the histopathological growth patterns of liver metastasis PJ Van Dam, EP Van Der Stok, LA Teuwen, GG Van den Eynden, ... British journal of cancer 117 (10), 1427-1441, 2017 | 215 | 2017 |
| Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models VL Bridgeman, PB Vermeulen, S Foo, A Bilecz, F Daley, E Kostaras, ... The Journal of pathology 241 (3), 362-374, 2017 | 208 | 2017 |
| Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer MD Forster, KJ Dedes, S Sandhu, S Frentzas, R Kristeleit, A Ashworth, ... Nature reviews Clinical oncology 8 (5), 302-306, 2011 | 148 | 2011 |
| A study of the decision outcomes and financial costs of multidisciplinary team meetings (MDMs) in oncology PB De Ieso, JI Coward, I Letsa, U Schick, M Nandhabalan, S Frentzas, ... British journal of cancer 109 (9), 2295-2300, 2013 | 91 | 2013 |
| Contrasting effects of sunitinib within in vivo models of metastasis JC Welti, T Powles, S Foo, M Gourlaouen, N Preece, J Foster, S Frentzas, ... Angiogenesis 15, 623-641, 2012 | 88 | 2012 |
| Mechanism of tumour vascularization in experimental lung metastases V Szabo, E Bugyik, K Dezso, N Ecker, P Nagy, J Timar, J Tovari, V Laszlo, ... The Journal of pathology 235 (3), 384-396, 2015 | 67 | 2015 |
| Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001 C Marth, R Tarnawski, A Tyulyandina, S Pignata, L Gilbert, D Kaen, ... International Journal of Gynecologic Cancer 32 (1), 2022 | 53 | 2022 |
| Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma VL Bridgeman, E Wan, S Foo, MR Nathan, JC Welti, S Frentzas, ... Molecular cancer therapeutics 15 (1), 172-183, 2016 | 45 | 2016 |
| Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in … TA Yap, DJ Kwiatkowski, J Desai, I Dagogo-Jack, M Millward, HL Kindler, ... Cancer Research 83 (8_Supplement), CT006-CT006, 2023 | 33 | 2023 |
| Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 … CP Carden, S Frentzas, M Langham, I Casamayor, AW Stephens, ... Journal of Clinical Oncology 27 (15_suppl), 3544-3544, 2009 | 28 | 2009 |
| Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical … SA Hurvitz, H Park, S Frentzas, CM Shannon, K Cuff, RW Eek, GT Budd, ... Journal of Clinical Oncology 39 (15_suppl), 1038-1038, 2021 | 24 | 2021 |
| AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors S Frentzas, T Meniawy, SCH Kao, R Wang, Y Zuo, H Zheng, W Tan J Clin Oncol 39 (15_suppl), 2583, 2021 | 18 | 2021 |
| A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors S Frentzas, HK Gan, R Cosman, J Coward, B Tran, M Millward, Y Zhou, ... Cell Reports Medicine 4 (11), 2023 | 14 | 2023 |
| A gut microbial signature for combination immune checkpoint blockade across cancer types A Gunjur, Y Shao, T Rozday, O Klein, A Mu, BW Haak, B Markman, D Kee, ... Nature medicine 30 (3), 797-809, 2024 | 12 | 2024 |
| Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study. J Coward, ARA Mislang, S Frentzas, CR Lemech, A Nagrial, X Jin, B Li, ... Journal of Clinical Oncology 39 (15_suppl), 2515-2515, 2021 | 12 | 2021 |
| # 88 Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: primary results of the phase 3 ENGOT-en9/LEAP-001 study C Marth, RG Moore, M Bidzinski, S Pignata, A Ayhan, MJ Rubio, M Beiner, ... International Journal of Gynecologic Cancer 34 (Suppl 1), 2024 | 10 | 2024 |
| 1021O Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies M Millward, S Frentzas, HK Gan, A Prawira, B Tran, J Coward, X Jin, B Li, ... Annals of Oncology 31, S705-S706, 2020 | 10 | 2020 |
| AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors S Frentzas, S Kao, R Gao, H Zheng, A Rizwan, N Budha, ... Journal for immunotherapy of cancer 11 (10), 2023 | 9 | 2023 |
| Trial in progress: a phase 1-2, first-in-Human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding … JR Vasselli, S Frentzas, AJ Weickhardt, PL de Souza, J Tang, T Wyant, ... J Clin Oncol 40 (16_suppl), 2022 | 9 | 2022 |
